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Background: Aberrant activation of the phosphatidylinositol 3-kinase (PI3K)/
mammalian target of rapamycin pathway due to alterations in PIK3CA (encoding
PI3Kα) frequently occurs in aST. We report safety findings from an ongoing, phase Ib
dose-escalation study of ALP (PI3Kα inhibitor) + PTX (NCT02051751).
Methods: Patients (pts) aged ≥18 years with aST (not amenable to resection/
progressed on standard therapy), ECOG performance status ≤2, adequate bone
marrow/organ function, and no prior treatment with PI3K or AKT inhibitors were
recruited. The primary objective was to determine the maximum tolerated dose (MTD)
and/or recommended Phase II dose of ALP + PTX based on dose-limiting toxicities
(DLTs) in Cycle 1. Dose escalation of ALP was guided by an adaptive Bayesian logistic
regression model with escalation with overdose control principle.
Results: As of Dec 7, 2015, 19 pts received oral ALP (300 mg [n = 6], 250 mg [n = 4], or
150 mg [n = 9] once daily [QD]) and IV PTX (80 mg/m2 once weekly [QW]). The
most common primary sites of cancer were breast (n = 5) and rectum (n = 3).
Treatment was discontinued in 18/19 pts due to disease progression (n = 12, 63%), pt
decision (n = 3, 16%), adverse events (AEs; n = 2, 11%; 1 pt for grade [G]3 dehydration,
G3 hyperglycemia, and G3 acute kidney injury; 1 pt for G4 neutropenia and G4
γ-glutamyltransferase increase), and physician decision (n = 1, 5%). DLTs occurred in
5/12 pts in the dose-determining set: 1/1 (100%) pt at 300 mg QD, 2/3 (67%) pts at
250 mg QD, and 2/8 (25%) pts at 150 mg QD. Six DLTs were reported: G2
hyperglycemia (n = 3), G4 hyperglycemia, G4 leukopenia, and G3 acute kidney injury
(each n = 1). The MTD of ALP + PTX (80 mg/m2 QW) was declared as 150 mg QD.
All 19 pts had ≥1 treatment-emergent AE. Grade 3/4 AEs occurred in 11 (58%) pts, the
most frequent being hyperglycemia (n = 6, 32%), diarrhea, anemia, lymphopenia,
neutropenia, and leukopenia (each n = 2, 11%).
Conclusions: In pts with aST, the MTD of ALP + PTX (80 mg/m2 QW) was 150 mg
QD. Due to the challenging safety profile of the combination and lack of available data
confirming the pharmacodynamics and/or clinical activity of ALP at 150 mg QD,
planned dose expansion in pts with breast cancer and head and neck squamous cell
carcinoma will not go forward.
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